摘要
目的观察阿奇霉素与布地奈德福莫特罗联合治疗支气管哮喘的疗效与安全性。方法将50例中重度支气管哮喘患者完全随机分为单药组和联合组,每组25例。单药组以布地奈德福莫特罗治疗,联合组以阿奇霉素联合布地奈德福莫特罗治疗。观察2组治疗后症状改善情况和肺功能变化及不良反应。结果单药组和联合组治疗1周及3个月后,哮喘症状评分均明显低于治疗前[单药组日间症状:(0.96±0.78)、(0.50±0.40)分比(3.76±1.16)分;单药组夜间症状:(0.76±0.38)、(0.22±0.02)分比(3.32±0.18)分;联合组日间症状:(0.56±0.51)、(0.28±0.08)分比(4.04.4-0.84)分;联合组夜间症状:(0.52±0.25)、(0.04±0.03)分I:L(3.44±0.20)分],1s用力呼气容树用力肺活量(FEV,/FVC)均明显高于治疗前[单药组:(65.5±2.0)%、(73.8±1.4)%比(58.5±1.8)%;联合组:(68.7±1.3)%、(82.1±0.8)%比(58.2±1.8)%],差异均有统计学意义(均P〈0.05)。治疗1周及3个月后,联合组哮喘症状评分明显低于单药组,FEVl/FVC明显高于单药组,差异均有统计学意义(均P〈0.05)。2组在治疗期间未发生严重不良反应。结论阿奇霉素联合布地奈德福莫特罗治疗支气管哮喘疗效确切,不良反应少。
Objective To explore the clinical effect of azithromycin combined with budesonide/formoterol turbuhaler for asthmatic patients. Methods Totally 50 patients were randomly divided into budesonide/formoterol turbuhaler for inhalation group ( single drug group, n = 25 ) and azithromycin and budesonide/formoterol turbuhaler for inhalation group( combined group, n = 25). The curative effect of tow groups and lung function change and ad- verse reaction were observed. Results After treatment for 1 week and 3 months, the scores of asthmatic symtoms in single drug group and combined group were less than those before treatment [ the symtoms of day time in single drug group : (0.96 ± O. 78 ), (0.50 ± O. 40) scores vs (3.76 ± 1.16) scores ; the symtoms of night time in single drug group : ( 0. 76 ± 0. 38 ), ( 0. 22 ± 0. 02 ) scores vs ( 3.32 ± 0. 18 ) scores ; the symtoms of day time in combined group: (0.56 ±0.51) , (0.28 ± 0. 08) scores vs(4.04 ± O. 84) scores; the symtoms of night time in combined group: (0.52 ± 0. 25 ), (0.04 ± O. 03 )scores vs(3.44 ± O. 20)scores ], and the FEVi/FVC were higher than those before treatment [ single drug group : (65.5 ± 2.0) %, (73.8 ± 1.4) % vs ( 58.5 ± 1.8) % ; combined group : ( 68.7 ± 1.3 ) %, ( 82.1 ± 0. 8) % vs (58.2 ± 1.8 ) % ], and there were significant differences ( all P 〈 O. 05 ). After treat- ment for 1 week and 3 months, the scores of asthmatic symtoms in combined group were less than those in single drug group, and the FEV1/FVC were higher than those in single drug group ( all P 〈 O. 05). Two groups in treat- ment period did not have serious adversr reactions. Conclusion Use of azithromycin and budesonide/formoterol turbuhaler in bronchial asthma has good curative effect.
出处
《中国医药》
2013年第9期1231-1233,共3页
China Medicine
关键词
哮喘
阿奇霉素
布地奈德福莫特罗
Asthma
Azithromycin
Budesonide/formoterol turbuhaler